In this episode, we will discuss, in brief the recent changes to the IGCCCG risk classification as well as recent advances in the management of germ cell tumours, beyond TIP. The role of miRNA in prognostication, as well the role of Brentuximab vedotin, guadecitabine and other newer molecules is explored.…

In this brief episode, we will talk about emerging data for the anti CLAUDIN 18.2 monoclonal antibody Zolbetuximab, in the MONO, GLOW and SPOTLIGHT trials. for advanced, unresectable or metastatic, HER2 negative gastric or GE junction adenocarcinomas.By Prashant Jambunathan

In the first part of this two part episode, we will talk about the role of Pembrolizumab (Keynote 062 for first line, Keynote 181 for second line) and Nivolumab (Checkmate 849) in both, first and later lines, in the management of advanced HER2 negative, gastric and GE junction cancers.By Prashant Jambunathan

We will discuss the emerging treatment landscape of Neuroblastoma, beyond Dinutuximab. We begin with Naxitamab, followed by the role of ALK inhibitors like Ceritinib and Crizotinib. We then move on to AURORA inhibitors, and other newer treatment modalities in phase 1 and 2 clinical trials.By Prashant Jambunathan

We will delve into Neuroblastoma in this episode, which is the most common extra-cranial solid tumour diagnosed in children. We will begin with a discussion of the clinical features, INRG staging, molecular features and prognostic factors. Treatment for all risk groups, including the COJEC chemotherapy based induction for high risk forms part of th…

This is part 2 of our two episode series on Peripheral T cell lymphomas. We will talk about the aggressive variants, which includes T cell lymphoma/leukemia, Systemic anaplastic large cell lymphoma and others. Disease biology, clinical presentations and treatment options are covered, with a brief discussion on newer treatment options.…

In the first part of this two part episode, we will talk the indolent peripheral T cell lymphomas, which include Mycosis fungicides, cutaneous ALCL and T cell large granular lymphocytic leukaemia. Clinical features, immunophenotyping and treatment options form the mainstay of the discussion.By Prashant Jambunathan

In this episode we will talk about the varied treatment landscape of MCL, ranging from Bendamustine - Rituximab and alternating RCHOP/RDHAP to the Nordic regimen. We will begin with a brief description of the clinical and immunophenotypical characteristics of MCL, followed by discussion of treatment in fit, as well as, older patients.…

We begin with the WHO classification of the Immunodeficiency associated lymphoproliferative disorders followed by a brief discussion of the management of HIV associated and post-transplant lymphoproliferative disorders.By Prashant Jambunathan

Starting with disease biology, clinical features and evaluation, we will discuss the management of Primary and secondary CNS lymphoma and Burkitt lymphoma, in this episode.By Prashant Jambunathan

We will talk about Primary Mediastinal B cell lymphoma, double hit lymphomas, GZL and T cell histiocyte rich diffuse large B cell lymphoma in this episode. Clinical features, immunophenotypic features and treatment options with prognosis are discussed.By Prashant Jambunathan

In the first part of this this two part episode, we will talk about the management strategies for early as well as advanced DLBCL. We will delve into the GCB and ABC subtypes, and discuss how RCHOP evolved as the standard of care of DLBCL. Second line salvage regimens, newer treatments, including a brief overview of CAR-T cell therapy is also discu…

In this episode we will continue our deliberation on indolent NHL, with the WHO classification of Marginal Zone Lymphoma and the management of the various subtypes. We will explore the role of Rituximab, Bendamustine, Ibrutinib, as well as the role of splenectomy in splenic MZL.By Prashant Jambunathan

In this episode we will discuss the prototypical indolent lymphoma, with a brief discussion on grades, followed by management strategies in low tumour and high tumour burden settings. In addition to using Bendamustine and Rituximab, the question of whether to use Obinituzumab in the first line, as well as, the role of maintenance anti-CD20 are also…

The clinical features, staging with Lugano system, the Deauville scoring system, as well as, prognostication with the International Prognostic index, Follicular lymphoma International prognostic index and the Lugano response criteria, on PET CT, forms the basis for this episode.By Prashant Jambunathan

We will begin our journey into Non-Hodgkin's lymphoma with a brief discussion of etiological associations, followed by development of the B and T cell from the common lymphoid progenitor. It begins with the master transcription factor PAX5 and NOTCH 1 for the B and T cell respectively. This is followed by a series of steps involving heavy and light…

In this episode, we will discuss the RAPIDO, PRODIGE 23 and CAO/ARO/AIO-12 trials, to enhance our understanding of the emerging role of total neoadjuvant treatment in rectal cancer, which is now the standard of care, according to consensus guidelines.By Prashant Jambunathan

In this episode, we will talk about the introduction of platinum compounds and immunotherapy in the management of early triple negative breast cancer with a view of improve pathological complete response rates. The discussion will include analysis of the GeparSixto, Brightness, Keynote 522, GeparNeuvo, Create-X and SYSUCC trials. We will also delve…

Screening for colorectal cancer is the topic of discussion in this presentation. Screening recommendations are unique for average risk and high risk individuals, and the frequency of modality of screening varies as well. We will also discuss in brief, the newer screening modalities, gaining traction worldwide, which include, CT / MR colonography an…

In this episode we will talk about the adjuvant treatment options in patients who have undergone curative resection for colon cancer. Decision making for whom to treat in Stage II and Stage III (everyone) is discussed. We will also delve into investigational adjuvant approaches, as well as, follow up of patients who have undergone curative resectio…

In this presentation we will talk about the role of immunotherapy in metastatic colorectal cancer, in the microsatellite instability - high sub-group. There is an overlap between the discussion in part 1, wherein we discussed landmark trials in this space. In this episode we will delve deeper into this topic to examine closely, the paradigm changin…

In this presentation we will talk about the treatment strategies of metastatic colorectal cancer. We will begin with a brief discussion of the chemotherapeutic backbone, such as FOLFOX and FOLFIRI, followed by anti-VEGF and anti-EGFR agents, as well as, targeted agents, such as those targeting the BRAF pathway. A brief description of immunotherapy …